The implementation of generative artificial intelligence (GenAI) in the pharmaceutical and healthcare sectors has the potential to tackle the challenges of high costs and poor patient experiences while enhancing efficiency and improving patient outcomes.
Kiran Raj, Practice Head of Disruptive Tech at GlobalData(a data and analytics company), emphasizes that GenAI is revolutionizing healthcare by driving a transformative shift across the value chain. With its ability to customize multi-format content and deliver precisely targeted communication, GenAI offers benefits to pharmaceutical companies and patients alike. However, responsible AI practices are crucial to build trust and manage risks in the industry.
GlobalData's Innovation Radar report, titled "New prescription: generative AI meets healthcare," provides an in-depth view of GenAI's implementation across the pharma value chain, covering areas such as research and development, imaging and diagnostics, and patient care and support. GenAI's ability to generate novel drug candidates based on researcher-provided criteria and constraints, as well as predict drug efficacy and safety, holds promise for advancing patient outcomes.
Comprising seasoned professionals and experts from the medical field, the IJCP editorial team is dedicated to delivering timely and accurate content and thriving to provide attention-grabbing information for the readers. What sets them apart are their diverse expertise, spanning academia, research, and clinical practice, and their dedication to upholding the highest standards of quality and integrity. With a wealth of experience and a commitment to excellence, the IJCP editorial team strives to provide valuable perspectives, the latest trends, and in-depth analyses across various medical domains, all in a way that keeps you interested and engaged.
Please login to comment on this article